Harpoon Therapeutics Strengthens Leadership Team
“I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy’s promotion. I look forward to benefiting from Jim’s extensive experience as we continue to advance the clinical development of our T cell engagers and execute toward multiple milestones in the next year,” said
Inducement Award under NASDAQ Listing Rule 5635(c)(4)
In connection with Mr. Bucher’s appointment,
The stock option grant has an exercise price per share equal to
The independent directors of Harpoon’s Board of Directors approved the award as an inducement material to Mr. Bucher’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “continue,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements relating to the effects of advancing Harpoon Therapeutics’ platforms, the company’s future business growth and partnerships, expectations regarding strengthening the company’s business team and other statements that are not historical fact. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Source: Harpoon Therapeutics Inc.